Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow on course for slim gains at open as Iran tensions clash with AI optimism
- Oil retreats from one-month high as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Karuna Therapeutics cut by analysts following news of Bristol-Myers Squibb acquisition
December 26, 2023 11:14 AM ESTKaruna Therapeutics Inc. (NASDAQ: KRTX) was downgraded by analysts at Leerink Partners, H.C. Wainwright and Maxim Group on Tuesday following news that the company will be acquired by Bristol-Myers Squibb (NYSE: BMY)for a total value of... More
Bristol-Myers Squibb (BMY) to buy RayzeBio (RYZB) for $4.1 billion
December 26, 2023 7:56 AM ESTPharmaceutical giant Bristol-Myers Squibb (NYSE: BMY) announced Tuesday that it is acquiring RayzeBio (NASDAQ: RYZB) for $4.1 billion, strengthening its oncology portfolio with promising radiopharmaceutical therapeutics (RPTs).
The deal, valued at $62.50 per RayzeBio share, was... More
